Aurobindo Pharma signs pact with Singapore-based Hilleman Labs for children vaccine

Aurobindo Pharma Limited's wholly-owned subsidiary Auro Vaccines Private Limited on Wednesday informed that it has entered into a licence agreement with Hilleman Laboratories Singapore Pte. Limited.

According to the filing, the agreement is about developing, manufacturing and commercializing a pentavalent vaccine candidate used in children vaccination. 

Auro Vaccines Private Limited will make milestone payments to Hilleman upon achieving certain development and clinical study outcomes. Hilleman will also be paid royalties upon commercialization of the vaccine candidate, the company said in a statement.

Shares of Aurobindo Pharma were under pressure in the morning session due to market volatility and trading at Rs876 per share lower by 0.47% on the BSE today.